# A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

> **NCT06294912** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 16 (actual)

## Conditions studied

- Malaria

## Interventions

- **OTHER:** Plasmodium falciparum
- **DRUG:** MK-7602
- **DRUG:** Artemether/lumefantrine
- **DRUG:** Primaquine
- **DRUG:** Artesunate
- **DRUG:** Atovaquone/proguanil

## Key facts

- **NCT ID:** NCT06294912
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-18
- **Primary completion:** 2025-01-06
- **Final completion:** 2025-01-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06294912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06294912, "A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06294912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*